ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate | 220746-98-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate
• 英文别名: ethyl 3-(4-(2-bromoethoxy)phenyl)-2-ethoxypropionate；ethyl 3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate；ethyl 3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropionate；ethyl 2-ethoxy-3-[4-(2-bromoethoxy) phenyl]propanoate；ethyl 2-ethoxy-3-[4-(2-bromoethoxy)phenyl]propanoate；ethyl 3-(4-(2-bromethoxy)phenyl)-2-ethoxypropanoate
• CAS: 220746-98-5
• 化学式: C₁₅H₂₁BrO₄
• 分子量: 345.233
• InChiKey: NSKMGRJJCCVBSH-UHFFFAOYSA-N

物化性质

• 沸点：
  423.9±40.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate 在 氢化钾 、 一水合肼 作用下， 以 N-甲基乙酰胺 、 乙醇 、 水 、 苯 为溶剂， 以2.4 g (96%)的产率得到ethyl 3-(4-(2-aminoethoxy)phenyl)-2-ethoxypropionate
  参考文献：
  名称：

  Compounds, their preparation and use

  摘要：

  本发明涉及式（I）的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、A、X、T、Q、Z、U、Y、Ar、p和n如规范中定义。这些化合物在治疗和/或预防由核受体介导的疾病中有用，特别是过氧化物酶体增殖激活受体（PPAR）。

  公开号：

  US06214820B1
• 作为产物：
  描述：

  4-苄氧基苯甲醛 在 palladium on activated charcoal 氢气 、 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 丙酮 为溶剂， 20.0 ℃ 、413.68 kPa 条件下， 反应 120.0h， 生成 ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate
  参考文献：
  名称：

  Novel thieno oxazine analogues as antihyperglycemic and lipid modulating agents

  摘要：

  A series of phenyl acetic acid and alpha-hydroxy propionic acid derivatives were synthesized. In vivo studies of the compounds indicated compound 2c as the most potent in one of the series, which has both glucose and lipid lowering properties. The syntheses and biological studies have been discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00976-9

文献信息

• Synthesis and Evaluation of 2-Nonylaminopyridine Derivatives as PPAR Ligands
  作者：Shinya Usui、Hiroki Fujieda、Takayoshi Suzuki、Naoaki Yoshida、Hidehiko Nakagawa、Michitaka Ogura、Makoto Makishima、Naoki Miyata

  DOI：10.1248/cpb.55.1053

  日期：——

  To find novel PPAR ligands, we prepared several 3-3 or 4-[2-(nonylpyridin-2-ylamino)ethoxy]phenyl}propanoic acid derivatives which were designed based on the structure of our previous PPARgamma ligand 1. In PPAR binding affinity assays, compound 4, which had an ethoxy group at the C-2 position of the propanoic acid of 1, showed selective binding affinity for PPARgamma. Compound 3, with an ethyl group

  为了找到新的PPAR配体，我们制备了几种3- 3或4- [2-（壬基吡啶-2-基氨基）乙氧基]苯基}丙酸衍生物，这些衍生物是根据我们以前的PPARγ配体1的结构设计的。亲和力测定法显示，化合物4在丙酸的C-2位置为1时具有乙氧基，对PPARγ具有选择性结合亲和力。发现在C-2位具有乙基的化合物3是PPARα/γ双重配体。已显示化合物1的间位异构体为PPARalpha配体。将甲基（7）和乙基（8）引入6的丙酸的C-2位置可进一步提高PPARalpha结合力。在基于细胞的反式激活分析中，化合物3和4对PPARalpha和PPARgamma表现出双重激动剂活性。发现化合物6是三重激动剂，并且化合物8被证明是选择性PPARα激动剂。在人体皮下脂肪细胞分化试验中，证明化合物3和4的最大活性高于罗格列酮。
• Benzothiazin and benzoxazin derivatives; their preparation and uses
  申请人：Dr. Reddy's Research Foundation

  公开号：US06130214A1

  公开（公告）日：2000-10-10

  The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel .beta.-aryl-.alpha.-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. ##STR1##

  本发明涉及新型抗肥胖和降胆固醇化合物，它们的衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。更具体地说，本发明涉及一般式（I）的新型β-芳基-α-氧基取代烷基羧酸，其衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。
• [EN] NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES TRICYCLIQUES ET LEUR UTILISATION EN MEDECINE, PROCEDE DE PREPARATION DE CES DERNIERS ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：WO1999019313A1

  公开（公告）日：1999-04-22

  (EN) Novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses.(FR) La présente invention concerne de nouveaux acides alkylcarboxyliques $g(b)-aryl-$g(a)-oxysubstitués répondant à la formule (I) et des compositions les contenant. Ces composés sont utilisés comme agents hypolipémiants et antihyperglycémiants.

  (EN) Novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses. (中文翻译) 新型的公式（I）中的$g(b)-芳基-$g(a)-氧代取代烷基羧酸和含有它们的组合物。这些化合物具有降血脂和抗高血糖的作用。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVELLES COMPOSITIONS HETEROCYCLIQUES ET LEUR UTILISATION EN MEDECINE; PROCEDES DE LEUR FABRICATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：WO1999016758A1

  公开（公告）日：1999-04-08

  (EN) The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.(FR) La présente invention concerne de nouveaux composés anti-obésité et hypocholestérolémiques, leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables et des compositions pharmaceutiquement acceptables les contenant. Plus particulièrement, cette invention se rapporte à de nouveaux acides alkylcarboxyliques $g(b)-aryl-$g(a)-oxysubstitués qui correspondent à la formule générale (I), ainsi qu'à leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables et à des compositions pharmaceutiquement acceptables les contenant.

  本发明涉及新型抗肥胖和降低胆固醇化合物，其衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂化物和包含它们的药学上可接受的组合物。更具体地说，本发明涉及一般式（I）的新型$g(b)-芳基-$g(a)-氧基取代的烷基羧酸，其衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂化物和包含它们的药学上可接受的组合物。
• [EN] NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES TRICYCLIQUES ET LEUR UTILISATION EN MEDECINE, PROCEDE DE PREPARATION DE CEUX-CI ET COMPOSITION PHARMACEUTIQUE LES CONTENANT
  申请人：REDDY RESEARCH FOUNDATION

  公开号：WO2000050414A1

  公开（公告）日：2000-08-31

  The present invention relates to novel hypolipidemic, antihyperglycemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel β-aryl-α-oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

  本发明涉及新型降脂、抗高血糖、抗肥胖和降胆固醇化合物，它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。更具体地说，本发明涉及一般式(I)的新型β-芳基-α-氧基取代烷基羧酸及其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。